But as more patients explore or discontinue these medications, functional and integrative medicine providers have a growing opportunity to offer complementary or alternative strategies that support similar metabolic pathwaysoften with fewer side effects
Ghrelin Receptor (GHS-R1a) Selective Activation Ipamorelin acts as a highly selective agonist of the growth hormone secretagogue receptor (GHS-R1a), mimicking the natural hormone ghrelin without affecting other pituitary hormone secretion: Selective binding to GHS-R1a receptors without stimulating ACTH, cortisol, or prolactin release Rapid onset of growth hormone pulse generation (peak levels within 40-60 minutes) No significant effect on appetite stimulation unlike other ghrelin mimetics Preserved feedback regulation through endogenous growth hormone-releasing inhibitory mechanisms Research indicates that ipamorelin releases growth hormone with potency and efficacy similar to GHRP-6 (EC50 approximately 1.3 nmol/L) but with superior selectivity for growth hormone secretion
Overall, the adverse events reported were similar to those expected with the GLP1-R agonist class of drugs
More serious deficiencies have the potential to impair heart and neurological function, leading to a wide range of serious symptoms, including but not limited to tinnitus, severe joint pain, memory problems, depression, anxiety, poor muscle function, ataxia and changes in reflexes
"If information is changing in as little as a day, how can we expect everyday Americans, doctors, or even HR and benefits leaders, to make sense of it all
Subjects in the control group were injected with 30 mL saline twice daily as placebo control
